Kilitch Drugs India Ltd Share Price & Stock Analysis

Kilitch Drugs India Ltd (BSE: 524500) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹702 Cr, it ranks #1,806 by market cap among the 6,197 Indian listed companies on FinBizNet, and #52 of 86 in Medicinal Chemicals and Botanical Products. At ₹215.52 (as of 16 Nov 2026), the share price is 19.6% below its 52-week high of ₹267.90 and 83.8% above its 52-week low of ₹117.25. The share price is up 13.4% over one year and up 12.5% over three months.

Key Metrics

Current Price₹215.52
Market Cap₹702 Cr
BSE Code524500
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio22.5
Return on Equity12.36%
Return on Assets5.56%
52-Week Range₹117.25 – ₹267.90
1-Year Price Change+13.4%
3-Month Price Change+12.5%
Beta (1Y)0.24
Dividend Yield0.00%
HeadquartersMumbai, Maharashtra
Websitekilitch.com

Latest Quarterly Results — Q2 FY27

Revenue₹50 Cr
Net Profit₹1 Cr
Net Margin2.8%
EPS (Basic)₹0.64
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Kilitch Drugs India Ltd Quarterly Revenue and Profit Trend

Kilitch Drugs India Ltd reported revenue of ₹50 Cr in Q2 FY27, up 2.7% from ₹49 Cr in Q2 FY26 and up 11.9% from ₹45 Cr in Q1 FY27. It posted a net profit of ₹1 Cr for the quarter, against a net profit of ₹8 Cr in Q2 FY26 (down 82.5%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹43 Cr (Q1 FY26) to ₹90 Cr (Q4 FY26). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹50 Cr₹1 Cr2.8%
Q1 FY27₹45 Cr₹2 Cr4.4%
Q4 FY26₹90 Cr₹15 Cr16.6%
Q3 FY26₹54 Cr₹4 Cr8.0%
Q2 FY26₹49 Cr₹8 Cr16.4%
Q1 FY26₹43 Cr₹2 Cr5.2%
Q4 FY25₹61 Cr₹10 Cr16.7%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 63.77% of Kilitch Drugs India Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 49.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Kilitch Drugs India Ltd

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional produ

Products and Services

1. Development and Operations of Pharmaceutical Business-This segment engages in the development and operation of pharmaceutical business.

Business Segments

1. Development and Operations of Pharmaceutical Business-100%

Kilitch Drugs India Ltd vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Kilitch Drugs India Ltd₹702 Cr22.512.36%₹50 Cr+13.4%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Kilitch Drugs India Ltd?

Kilitch Drugs India Ltd is trading at ₹215.52, with a market capitalisation of ₹702 Cr.

Which sector does Kilitch Drugs India Ltd belong to?

Kilitch Drugs India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Kilitch Drugs India Ltd?

Kilitch Drugs India Ltd has a P/E of 22.5 and a return on equity of 12.36%.

What is the stock symbol of Kilitch Drugs India Ltd?

Kilitch Drugs India Ltd is listed on the BSE under the scrip code 524500.

How has Kilitch Drugs India Ltd's share price moved over the past year?

Kilitch Drugs India Ltd's share price is up 13.4% over one year and up 12.5% over three months. Its 52-week range is ₹117.25 to ₹267.90.

What were Kilitch Drugs India Ltd's latest quarterly results?

In Q2 FY27, Kilitch Drugs India Ltd reported revenue of ₹50 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.64 (consolidated, parsed from the company's exchange filing).

How have Kilitch Drugs India Ltd's revenue and profit changed over the past year?

Kilitch Drugs India Ltd reported revenue of ₹50 Cr in Q2 FY27, up 2.7% from ₹49 Cr in Q2 FY26 and up 11.9% from ₹45 Cr in Q1 FY27.

What is the promoter holding in Kilitch Drugs India Ltd?

Promoters held 63.77% of Kilitch Drugs India Ltd's shares as of Sept 2026, unchanged from Sept 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.